Well Sherlock, Cytodyn deserved the FDA letter. The

New Post Public Reply Private Reply Replies (0) Message Board
My69z sherlock57 #161870
635
Well Sherlock, Cytodyn deserved the FDA letter.

The court documents: 
Warned for over 1 year of 100+ Hiv-BLA defencies. Warned by FDA how they were not telling that story to shareholders.

Covid hit :
Leronlimab performed miraculously best in the world. Past mgt still chose to stay course on BLA "progress".

FDA rightfully felt mgt was trying to force a Covid approval, so Leronlimab could get embedded. Sweeping the BLA half-truths, under the rug.

Court documents showed that FDA letter went through every head of departments, signed off by legal department.

Two reasons:
1) FDA knew LL worked. Conveniently left out LL was the only FDA approval for hospitals who followed the protocol.

2) It was a warning to any firm that you will have to bring everyone of these FDA heads, into court --- let alone on your own dime.

Govt's too got the message that "somethings not right here" on Cytodyn & knew "Cytodyn" would also put at risk their US Govt dealings.

All worldwide covid deals died.
Dr. Otto's eAP was shut down. No warning.

Told to enroll people into a trial.

Also due to past mgt. using message brds to manipulate the narrative, because 99% retail invest with emotions. 

Morals & legalities are oil n water.

That's the short of that.

On 2 vs 4 dosing:
it was me who posted that Dr. J interview source back then. But, i also said you have to listen 1 min longer when Dr. J says he believes the FDA still thought LL was an immunosuppressive. 

So did he until right before that meeting --- which he was not a member of --- & said the FDA was not going to take time during a pandemic, to look @ that.

On the FDA E-mail comments about "approval" & Dr. J :

The FDA exchange saying won't even look, before denying. That was due to past mgt causing FDA so many headaches & they took it as trying to bully an approval out of them -- under Covid. 

Think about what Tesla initially did after being told by a couple states they could not sell cars in their state.

Tesla pushed ahead asap & became embedded because people were being a vocal support. Tesla gamble paid off. 

Similar was Cytodyn's past mgt tactics.
Get covid embedded -- medical community falls in love --- wages public war FOR them later, if post-covid, FDA removed LL.

On FDA e-mail saying Dr. J comes off as a con-man:

They were saying the opposite of what people were ranting about. FDA was saying he's risking his reputation being attached, to a con man, as they were @ that point considering Cytodyn "ceo" to be. 

Which ironically, the court documents showed what about that "ceo"? Telling the CRO to submit the incomplete BLA. 

Even AFTER the 100 defencies knowledge. Well he's now in fed lock-up. 9 yrs to ponder.

But keep in mind, Dr. J was not an official Cytodyn contact on DSMB meeting. It is why he said he asked DSMB in the hallway (that is a very important legalality right there), if they were seeing signaling needs for 4 doses in later stage Covid patients. 

They did not answer him. Dr. Kelly was @ that point in charge.

1 thing everyone never mentioned from all that now backdated chaos is:

1) FDA historically granted Cytodyn many requested designations. Mgt not once, advanced any of them. 

Would support an FDA defence they're "holding Cytodyn back @ being in cahoots with pharma".

2) Being Dr. J was not an official of Cytodyn, nothing the FDA referenced about him, was illegal against Cytodyn. 

Again, morals Vs legalities.

On "Gilead":
It was me who posted one of our DSMB members also advised Gilead before. I pointed it out because that was around time Cytodyn was to do a LL Vs Remdesevair. Also pointed out to keep in mind --- he was also a highly sought out consultant. 

Every company was scratching to compile Safety boards during the pandemic. Ironically, the court documents showed in Dr. J's letter to all those constituents, 1 person was also the mentioned past DSMB member. 

If Dr. J felt he was an issue on the 2 Vs 4 dosing, he would not have included him on the CC's, in his personal mail. 

Who did Dr. J exclude in his personal e-mail ? The "ceo" 

Gilead:
The only "proof" they've held back LL for years, is rooted in all of the above. A very weak attachment that would border on slander. 

But again, shareholder emotions that blocks reading patents & documents.

Said all, all of this to say --- ( & there is more, but you get it ).......I won't dig for my posts saying since Dr. J joined January 2024 --- ( although his signature is on Sept 2023 filings), & especially since 1st mTNBC news of 36+ months, that if, if Dr. J & Cytodyn roll this out right, the FDA will not be any issue & Cytodyn could become the most dominant pharma in history. 

Patents. Safety. Efficacy. Profit margins. Etc, etc....

Now look our optics post "36+". 
Absolutely unfathomable to an imagination.

So the past is why Dr. J ulis going the press release conservative route, for now. It's working too because it's building the Sequencing facts through science data.

So yes, agreed 100% Dr. J has a very stacked approach to be released as Cytodyn continues being recognized for what Leronlimab is.

I was as usual laughed @ & in-directly sarcastic comments when I said:

* LL will break the typical pharma mode of stealing a drug & dominating.

* FDA will not block LL.
Working with Cytodyn in many ways.

* We will later find out the FDA & the DOD have been working with Cytodyn / Dr. J / LL.

I posted days ago of finding so far 5 direct/indirect links of Leronlimab & DOD via people & grant funding. So shall see.

If Cytodyn updates on all trials & the eAP progressions, Cytodyn will have over 10 patient types, collecting Cold/Hot & PD-L1 data, etc...

Becoming more significant than even every fully marketed pharma drug.

Another daym 1st for Leronlimab.

Our only share price "resistance" has been --- awareness.
Yes sir. Cytodyn is now legally sequencing our growth into a pharma powerhouse, through Leronlimab.

: )

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 573

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 100

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Secretariat's Legacy Bottled: Bourbon Honors Belmont Win

Updated Category News Views 28

A Toast to Racing History When you think about groundbreaking victories, Secretariat's name is right up there. Now, they’re bottling that history into bourbon. It's not just any day you get a drink inspired by a 31-length victory. Thoroughbred fans and whiskey lovers, listen up because Thirty-One Lengths Bourbon is bringing Secretariat back into the spotlight....

Continue Reading
China Automotive Systems Achieves Record Revenue in 2024

Updated Category News Views 202

Record Revenue Growth at China Automotive Systems China Automotive Systems, Inc. (NASDAQ: CAAS) has reported a remarkable increase in its revenue for the fiscal year 2024, achieving an all-time high of $650.9 million. This represents a significant 12.9% increase from the previous year's revenue of $576.4 million, demonstrating the company's strength in the competitive...

Continue Reading
Future of Energy Storage: A Market Growth Journey Ahead

Updated Category News Views 271

Understanding the Energy Storage Market Potential The global energy storage sector is on the brink of significant growth, projected to escalate from a value of USD 58.9 billion in 2024 to an astonishing USD 204.8 billion by 2033. This remarkable trajectory represents an impressive compound annual growth rate (CAGR) of 14.8%. As the world leans more heavily towards...

Continue Reading
Celebrated Legal Innovators: Reuben Raucher & Blum Shine Bright

Updated Category News Views 116

Reuben Raucher & Blum Earn Legal Visionary Recognition Boutique law firm Reuben Raucher & Blum (RRB), based in Los Angeles, has recently gained significant recognition for its exceptional legal expertise. Partners Tim Reuben and Stephanie Blum have been celebrated as Legal Visionaries in Business of Law magazine. This award acknowledges their remarkable leadership and...

Continue Reading
Baker Hughes Welcomes Ahmed Moghal as New CFO to Drive Growth

Updated Category News Views 294

Baker Hughes Announces New CFO Appointment HOUSTON and LONDON — Baker Hughes Company (NASDAQ: BKR) has officially appointed Ahmed Moghal as the new Chief Financial Officer. Moghal, who has been instrumental in the organization’s financial strategies as the CFO of Industrial & Energy Technology (IET), steps into this pivotal role immediately. His vast experience within...

Continue Reading